These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27930863)

  • 1. Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes.
    Kim HJ; Kim DJ
    J Diabetes Investig; 2017 Jul; 8(4):431-433. PubMed ID: 27930863
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.
    Zinman B; Marso SP; Christiansen E; Calanna S; Rasmussen S; Buse JB;
    Diabetes Care; 2018 Aug; 41(8):1783-1791. PubMed ID: 29903847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
    Scheen AJ; Piérard L; Krzesinski JM; Paquot N
    Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.
    Bouchi R; Nakano Y; Fukuda T; Takeuchi T; Murakami M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Endocr J; 2017 Mar; 64(3):269-281. PubMed ID: 27916783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.
    Crowley MJ; McGuire DK; Alexopoulos AS; Jensen TJ; Rasmussen S; Saevereid HA; Verma S; Buse JB
    Diabetes Care; 2020 Sep; 43(9):e108-e110. PubMed ID: 32647053
    [No Abstract]   [Full Text] [Related]  

  • 6. London buses: A cardiovascular outcome trial equivalent?
    Grant PJ
    Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
    [No Abstract]   [Full Text] [Related]  

  • 7. Liraglutide and cardiovascular outcomes in type 2 diabetes.
    Jones B
    Ann Clin Biochem; 2016 Nov; 53(6):712. PubMed ID: 28071177
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.
    Athyros VG; Katsiki N; Tentolouris N
    Curr Vasc Pharmacol; 2016; 14(5):469-473. PubMed ID: 27633290
    [No Abstract]   [Full Text] [Related]  

  • 9. [Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment Lowering of cardiovascular risk in treatment with liraglutide - Results of the LEADER].
    Olšovský J
    Vnitr Lek; 2016; 62(7-8):613-5. PubMed ID: 27627086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes.
    Kosiborod M
    J Diabetes Complications; 2017 Feb; 31(2):517-519. PubMed ID: 27839923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials.
    Birnbaum Y; Ye Y; Bajaj M
    J Diabetes Complications; 2017 Feb; 31(2):291-294. PubMed ID: 27780670
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
    Peterson SC; Barry AR
    Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
    Verma S; Bhatt DL; Bain SC; Buse JB; Mann JFE; Marso SP; Nauck MA; Poulter NR; Pratley RE; Zinman B; Michelsen MM; Monk Fries T; Rasmussen S; Leiter LA;
    Circulation; 2018 May; 137(20):2179-2183. PubMed ID: 29760228
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial.
    Gilbert MP; Bain SC; Franek E; Jodar-Gimeno E; Nauck MA; Pratley R; Réa RR; Kerr Saraiva JF; Rasmussen S; Tornøe K; von Scholten BJ; Buse JB;
    Ann Intern Med; 2019 Mar; 170(6):423-426. PubMed ID: 30508430
    [No Abstract]   [Full Text] [Related]  

  • 15. After 10 Years of Clinical Trials with Liraglutide in Diabetes, What do we Know About its Effects on Clinical Cardiovascular Outcomes?
    Doggrell SA
    Rev Recent Clin Trials; 2015; 10(1):68-77. PubMed ID: 25881636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
    Ingelfinger JR; Rosen CJ
    N Engl J Med; 2016 Jul; 375(4):380-2. PubMed ID: 27331286
    [No Abstract]   [Full Text] [Related]  

  • 17. Mediation analysis of time-to-event endpoints accounting for repeatedly measured mediators subject to time-varying confounding.
    Vansteelandt S; Linder M; Vandenberghe S; Steen J; Madsen J
    Stat Med; 2019 Oct; 38(24):4828-4840. PubMed ID: 31411779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
    Cusi K
    Curr Opin Lipidol; 2016 Dec; 27(6):633-635. PubMed ID: 27805974
    [No Abstract]   [Full Text] [Related]  

  • 19. Which person with diabetes should receive cardioprotective glucose-lowering medicines?
    Bloomgarden ZT
    J Diabetes; 2020 May; 12(5):352-353. PubMed ID: 32119186
    [No Abstract]   [Full Text] [Related]  

  • 20. ASPIRIN FOR PRIMARY PREVENTION IN PATIENTS WITH TYPE 2 DIABETES.
    Foster JG; Wood SK; Pfeffer MA; DeMets DL; Garber A; Hennekens CH
    Endocr Pract; 2018 Oct; 24(10):925-927. PubMed ID: 29975578
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.